AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9355055 — intervention group
Group type: COMPARATOR
Intervention: Lido Multi-Joint II
Number of subjects: 41
Study 7524592 — intervention group
Group type: EXPERIMENTAL
Intervention: aprotinin (total dose 2,000,000 kallikrein inhibiting units)
Number of subjects: 17
Study 7524592 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17
Study 2908755 — intervention group
Group type: EXPERIMENTAL
Intervention: Balsalazide (BSZ) 1 g b.d. orally
Number of subjects: 79
Study 2908755 — intervention group
Group type: COMPARATOR
Intervention: Sulphasalazine (SASP) 1 g b.d. orally
Number of subjects: 79
Study 2908755 — intervention group
Group type: EXPERIMENTAL
Intervention: Balsalazide (BSZ)
Number of subjects: 79
Study 2908755 — intervention group
Group type: COMPARATOR
Intervention: Sulphasalazine (SASP)
Number of subjects: 79
Study 31345088 — intervention group
Group type: EXPERIMENTAL
Intervention: Signposts program
Number of subjects: 71
Study 31345088 — intervention group
Group type: COMPARATOR
Intervention: Generic telephone support
Number of subjects: 71
Study 28460409 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg TA
Number of subjects: 224
Study 28460409 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg TA
Number of subjects: 224
Study 28460409 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 224
Study 27078269 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundamental Movement Skills (FMS) training for DCD group (DCD[exp])
Number of subjects: 84
Study 27078269 — intervention group
Group type: COMPARATOR
Intervention: Control group (DCD[con])
Number of subjects: 84
Study 24605299 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency assisted turbinoplasty (RF)
Number of subjects: 60
Study 24605299 — intervention group
Group type: COMPARATOR
Intervention: Microdebrider assisted turbinoplasty (MD)
Number of subjects: 60
Study 22968854 — intervention group
Group type: EXPERIMENTAL
Intervention: 375 mg fosphenytoin sodium
Number of subjects: 12
Study 22968854 — intervention group
Group type: COMPARATOR
Intervention: 250 mg phenytoin sodium
Number of subjects: 12
Study 22968854 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosphenytoin sodium (375, 563, and 750 mg)
Number of subjects: 12
Study 22968854 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosphenytoin sodium
Number of subjects: 12
Study 22968854 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin sodium
Number of subjects: 12
Study 20870109 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐piece acrylic foldable IOL (AcrySof SA60AT)
Number of subjects: 125
Study 20870109 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐piece acrylic foldable IOL (AcrySof MA60AC)
Number of subjects: 125
Study 20870109 — intervention group
Group type: COMPARATOR
Intervention: Both IOL groups
Number of subjects: 125
Study 18394567 — intervention group
Group type: EXPERIMENTAL
Intervention: Spheramine (stereotactic implantation into the striatum)
Number of subjects: 6
Study 18394567 — intervention group
Group type: COMPARATOR
Intervention: Spheramine (bilateral implantation into the postcommissural putamen)
Number of subjects: 6
Study 15943672 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal paired‐associate and verbal learning tests of various lengths
Number of subjects: 208
Study 15943672 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal paired‐associate and verbal learning tests
Number of subjects: 208
Study 15943672 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal test lengths for verbal paired‐associate and verbal list‐learning tests
Number of subjects: 208
Study 12581490 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebif (IFN-beta1a) at 44 microg t.i.w.
Number of subjects: 0
Study 12581490 — intervention group
Group type: COMPARATOR
Intervention: Betaseron (IFN-beta1b)
Number of subjects: 0
Study 10355071 — intervention group
Group type: COMPARATOR
Intervention: Intravenous enalaprilat (initial dose: 2.5 mg; repetitive application of 2.5 mg every 30 min until a cumulative dose of 10 mg)
Number of subjects: 46
Study 10355071 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerine (initial dose: 0.8 mg; repetitive application of 0.8 mg every 10 min until a cumulative dose of 3.2 mg)
Number of subjects: 46
Study 8574735 — intervention group
Group type: COMPARATOR
Intervention: omeprazole
Number of subjects: 65
Study 8574735 — intervention group
Group type: COMPARATOR
Intervention: lansoprazole
Number of subjects: 65
Study 8574735 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole+plaunotol
Number of subjects: 65
Study 8574735 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole+clarithromycin
Number of subjects: 65
Study 8574735 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole+plaunotol+clarithromycin
Number of subjects: 65
Study 1790550 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of oral ubidecarenone daily
Number of subjects: 20
Study 1790550 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ubidecarenone)
Number of subjects: 20
Study 7214795 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 2 mg/day
Number of subjects: 15
Study 7214795 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocortinbutyl (FCB) 40 mg/day
Number of subjects: 15
Study 7214795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 29847252 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cost information displayed (66.2% acceptance)
Number of subjects: 1211
Study 29847252 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cost information displayed for another person (68.0% acceptance)
Number of subjects: 1211
Study 29847252 — intervention group
Group type: COMPARATOR
Intervention: No total cost information displayed (58.0% acceptance)
Number of subjects: 1211
Study 29847252 — intervention group
Group type: COMPARATOR
Intervention: No total cost information displayed for another person (56.4% acceptance)
Number of subjects: 1211
Study 29489106 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia with continuous anesthetic
Number of subjects: 120
Study 29489106 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia with bolus anesthetic
Number of subjects: 120
Study 29489106 — intervention group
Group type: COMPARATOR
Intervention: Bilateral blockade of the cross-space belly
Number of subjects: 120
Study 29489106 — intervention group
Group type: COMPARATOR
Intervention: Multimodal analgesia system
Number of subjects: 120
Study 23630403 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 382
Study 23630403 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 382
Study 23941761 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (LaCO3)
Number of subjects: 38
Study 23941761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 19861658 — intervention group
Group type: EXPERIMENTAL
Intervention: History of PAD
Number of subjects: 299
Study 19861658 — intervention group
Group type: COMPARATOR
Intervention: No history of PAD
Number of subjects: 299
Study 18250184 — intervention group
Group type: EXPERIMENTAL
Intervention: REClari (Clarithromycin)
Number of subjects: 371
Study 18250184 — intervention group
Group type: COMPARATOR
Intervention: RECipro (Ciprofloxacin)
Number of subjects: 371
Study 18250184 — intervention group
Group type: EXPERIMENTAL
Intervention: M vaccae immunotherapy
Number of subjects: 371
Study 16427745 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 0
Study 16427745 — intervention group
Group type: COMPARATOR
Intervention: Time‐matched comparison condition (health education and scheduled, reduced smoking)
Number of subjects: 0
Study 12824212 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiluted smallpox vaccine
Number of subjects: 90
Study 12824212 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted smallpox vaccine (1:3.2)
Number of subjects: 90
Study 12824212 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted smallpox vaccine (1:10)
Number of subjects: 90
Study 12824212 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted smallpox vaccine (1:32)
Number of subjects: 90
Study 12824212 — intervention group
Group type: COMPARATOR
Intervention: Vaccinia‐naive participants (undiluted vaccine)
Number of subjects: 90
Study 12824212 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐naive participants
Number of subjects: 90
Study 12824212 — intervention group
Group type: COMPARATOR
Intervention: Vaccinia‐naive participants
Number of subjects: 90
Study 12212115 — intervention group
Group type: EXPERIMENTAL
Intervention: BZX (bizhongxiao decoction)
Number of subjects: 96
Study 12212115 — intervention group
Group type: COMPARATOR
Intervention: MTX (methotrexate)
Number of subjects: 96
Study 12212115 — intervention group
Group type: EXPERIMENTAL
Intervention: BZX
Number of subjects: 96
Study 12212115 — intervention group
Group type: COMPARATOR
Intervention: MTX
Number of subjects: 96
Study 8814042 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzyl benzoate application to mattresses and carpets in addition to usual mite control measures.
Number of subjects: 26
Study 8814042 — intervention group
Group type: COMPARATOR
Intervention: Usual house dust mite control measures including vinyl covers for mattresses and pillows.
Number of subjects: 26
Study 8814042 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzyl benzoate application to mattresses and carpets.
Number of subjects: 26
Study 8814042 — intervention group
Group type: COMPARATOR
Intervention: Usual house dust mite control measures.
Number of subjects: 26
Study 8814042 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzyl benzoate application and usual control measures.
Number of subjects: 26
Study 1582788 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical carteolol 1%
Number of subjects: 15
Study 1582788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 4015065 — intervention group
Group type: EXPERIMENTAL
Intervention: apalcillin 75 mg/kg
Number of subjects: 21
Study 4015065 — intervention group
Group type: EXPERIMENTAL
Intervention: apalcillin 150 mg/kg
Number of subjects: 21
Study 4015065 — intervention group
Group type: EXPERIMENTAL
Intervention: apalcillin 225 mg/kg
Number of subjects: 21
Study 4015065 — intervention group
Group type: EXPERIMENTAL
Intervention: apalcillin (all doses)
Number of subjects: 21
Study 31727915 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 60
Study 31727915 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60
Study 31727915 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 60
Study 31727915 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 30073307 — intervention group
Group type: EXPERIMENTAL
Intervention: e-book readings supplemented with vocabulary instruction (scaffolding through explanations in Spanish, repetition in English, checks for understanding, and highlighted morphology)
Number of subjects: 288
Study 30073307 — intervention group
Group type: COMPARATOR
Intervention: read-only condition (control group)
Number of subjects: 288
Study 26825021 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-30 mg/24h morphine SR
Number of subjects: 124
Study 26825021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 1441866 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml bupivacaine 0.125% with 12.5 micrograms epinephrine (test dose)
Number of subjects: 40
Study 1441866 — intervention group
Group type: COMPARATOR
Intervention: 10 ml normal physiologic saline (control)
Number of subjects: 40
Study 23134737 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle Strength Training (ST)
Number of subjects: 69
Study 23134737 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle Power Training (PT)
Number of subjects: 69
Study 23134737 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 69
Study 21080835 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 1653
Study 21080835 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1653
Study 18459121 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation with yoga (and psychoeducation)
Number of subjects: 46
Study 18459121 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy with hypnosis (and psychoeducation)
Number of subjects: 46
Study 18459121 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation alone
Number of subjects: 46
Study 16392991 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional Treatment Foster Care (MTFC)
Number of subjects: 81
Study 16392991 — intervention group
Group type: COMPARATOR
Intervention: Group Care (GC)
Number of subjects: 81
Study 12507634 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein (15 mg, n = 5)
Number of subjects: 17
Study 12507634 — intervention group
Group type: COMPARATOR
Intervention: Alpha-tocopherol (100 mg, n = 6)
Number of subjects: 17
Study 12507634 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 17
Study 10570588 — intervention group
Group type: EXPERIMENTAL
Intervention: OralCDx analysis
Number of subjects: 945
Study 10570588 — intervention group
Group type: COMPARATOR
Intervention: Scalpel biopsy
Number of subjects: 945
Study 8888117 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin supplementation
Number of subjects: 0
Study 1497931 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidoflazine 1 mg/kg intravenously over a period of 20 min before initiation of cardiopulmonary bypass
Number of subjects: 93
Study 1497931 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 93
Study 3914085 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent traction
Number of subjects: 100
Study 3914085 — intervention group
Group type: COMPARATOR
Intervention: No traction
Number of subjects: 100
Study 3914085 — intervention group
Group type: EXPERIMENTAL
Intervention: Static traction
Number of subjects: 100
Study 3914085 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual traction
Number of subjects: 100
Study 30596265 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert moderated vaccine social media (VSM) website
Number of subjects: 367
Study 30596265 — intervention group
Group type: COMPARATOR
Intervention: Publicly available parenting and vaccine-focused blogs and discussion forums
Number of subjects: 367
Study 30381628 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation
Number of subjects: 14564
Study 30381628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14564
Study 25952586 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-games group (N=24)
Number of subjects: 47
Study 25952586 — intervention group
Group type: COMPARATOR
Intervention: Traditional therapy group (N=23)
Number of subjects: 47
Study 24841348 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node dissection (SLND)
Number of subjects: 0
Study 24841348 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual tracer technique
Number of subjects: 0
Study 24841348 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted axillary dissection (TAD)
Number of subjects: 0
Study 20438194 — intervention group
Group type: EXPERIMENTAL
Intervention: RELATE + Couple CARE
Number of subjects: 59
Study 20438194 — intervention group
Group type: COMPARATOR
Intervention: RELATE
Number of subjects: 59
Study 16370155 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Number of subjects: 63
Study 16370155 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 63
Study 11952579 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) ointment (0.2%)
Number of subjects: 60
Study 11952579 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem hydrochloride (DTZ) cream (2%)
Number of subjects: 60
Study 9458470 — intervention group
Group type: EXPERIMENTAL
Intervention: SPf66 (0.5 mg or 1.0 mg)
Number of subjects: 150
Study 9458470 — intervention group
Group type: EXPERIMENTAL
Intervention: SPf66 (high dose Colombian vaccine)
Number of subjects: 150
Study 9458470 — intervention group
Group type: EXPERIMENTAL
Intervention: SPf66
Number of subjects: 150
Study 9458470 — intervention group
Group type: COMPARATOR
Intervention: Inactivated polio vaccine
Number of subjects: 150
Study 7872410 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral and bilateral tachistoscopic stimulation (the Dimond paradigm)
Number of subjects: 0
Study 7872410 — intervention group
Group type: EXPERIMENTAL
Intervention: Poffenberger paradigm with varying memory load
Number of subjects: 0
Study 7872410 — intervention group
Group type: COMPARATOR
Intervention: Poffenberger paradigm with field/hand/load interaction
Number of subjects: 0
Study 3127188 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin sodium capsules 400 mg with enteral feedings (Ensure) at 100 ml/h for ten hours
Number of subjects: 6
Study 3127188 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin sodium capsules 400 mg without enteral feedings
Number of subjects: 6
Study 11564991 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg o.d. (or valsartan 80 mg + HCTZ 12.5 mg o.d. after 4 weeks if needed)
Number of subjects: 690
Study 11564991 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg o.d. (or amlodipine 10 mg o.d. after 4 weeks if needed)
Number of subjects: 690
Study 30720640 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based aerobic interval training (24 sessions)
Number of subjects: 19
Study 30720640 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 19
Study 29474934 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-dose regimen of HPV vaccine
Number of subjects: 24000
Study 29474934 — intervention group
Group type: COMPARATOR
Intervention: 2-dose regimen of HPV vaccine
Number of subjects: 24000
Study 29474934 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated girls (observational study)
Number of subjects: 24000
Study 26955763 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Care Pathway for Childhood Asthma intervention, which includes an electronic guide and train-the-trainer education for chronic disease management health professionals.
Number of subjects: 0
Study 26955763 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified, but implied to be standard care without the intervention.
Number of subjects: 0
Study 24641624 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (8 g day(-1) containing 1.6 g day(-1) eicosapentaenoic acid + docosahexaenoic acid)
Number of subjects: 36
Study 24641624 — intervention group
Group type: COMPARATOR
Intervention: High oleic sunflower oil (8 g day(-1))
Number of subjects: 36
Study 24641624 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 36
Study 22717030 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 37
Study 22717030 — intervention group
Group type: COMPARATOR
Intervention: Ketamine
Number of subjects: 37
Study 22717030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 20802297 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir monotherapy
Number of subjects: 225
Study 20802297 — intervention group
Group type: COMPARATOR
Intervention: Darunavir/ritonavir triple drug regimen
Number of subjects: 225
Study 16782174 — intervention group
Group type: EXPERIMENTAL
Intervention: IL6 polymorphisms (specifically the -572 G>C polymorphism)
Number of subjects: 3027
Study 16782174 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 3027
Study 15157691 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (10 sessions over 3-4 weeks at anti-pain acupoints)
Number of subjects: 24
Study 15157691 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (10 sessions over 3-4 weeks at placebo-points)
Number of subjects: 24
Study 11233459 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 59
Study 11233459 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 59
Study 9442782 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost (0.005%) administered once daily for 6 months
Number of subjects: 277
Study 9442782 — intervention group
Group type: COMPARATOR
Intervention: Timolol (0.5%) administered twice daily for 6 months
Number of subjects: 277
Study 9442782 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost (0.005%) administered once daily for 18 months
Number of subjects: 277
Study 9442782 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost (0.005%) administered once daily for 24 months
Number of subjects: 277
Study 7992902 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 micrograms/kg
Number of subjects: 10
Study 7992902 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 4.5 micrograms/kg
Number of subjects: 10
Study 7992902 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 0.75 mg/kg
Number of subjects: 10
Study 7992902 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 4.3 micrograms/kg
Number of subjects: 10
Study 7992902 — intervention group
Group type: COMPARATOR
Intervention: Desflurane (control)
Number of subjects: 10
Study 2729906 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipram (pipemidic acid) 200 mg daily at bedtime for 6 months
Number of subjects: 70
Study 2729906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 2729906 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipram (pipemidic acid)
Number of subjects: 70
Study 5100498 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual introduction of treatment with levodopa
Number of subjects: 20
Study 5100498 — intervention group
Group type: COMPARATOR
Intervention: Rapid introduction of treatment with levodopa
Number of subjects: 20
Study 5100498 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly patients (aged 65 and over)
Number of subjects: 20
Study 5100498 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger patients (under 65)
Number of subjects: 20
Study 5100498 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate of increasing the dose of levodopa
Number of subjects: 20
Study 31573644 — intervention group
Group type: EXPERIMENTAL
Intervention: Redesigned simulation and redistribution of clinical hours in intervention group
Number of subjects: 586